115621-95-9|SDZ-62-434|5-(4-(piperidin-1-yl)phenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline dihydrochloride|-范德生物科技公司

SDZ-62-434

NMR下载 COA and HPLC MSDS下载
names：
5-(4-(piperidin-1-yl)phenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline dihydrochloride
CAS号：
115621-95-9
MDL Number：
MF(分子式)： C22H25Cl2N3 MW(分子量)： 402.363
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	5-(4-(piperidin-1-yl)phenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline dihydrochloride
英文别名	SDZ-62-434; SDZ 62 434; SDZ62434
CAS号	115621-95-9
SMILES	[H]Cl.[H]Cl.C12=NCCN1C(C3=CC=C(N4CCCCC4)C=C3)=CC5=C2C=CC=C5
Inchi	InChI=1S/C22H23N3.2ClH/c1-4-13-24(14-5-1)19-10-8-17(9-11-19)21-16-18-6-2-3-7-20(18)22-23-12-15-25(21)22;;/h2-3,6-11,16H,1,4-5,12-15H2;2*1H
InchiKey	BKOQATFPPHQOQH-UHFFFAOYSA-N
分子式 Formula	C22H25Cl2N3
分子量 Molecular Weight	402.363
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	SDZ-62-434(CAS:115621-95-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	SDZ-62-434 is a platelet activating factor inhibitor potentially for the treatment of cancer. Anti-inflammatory effects of SDZ-62-434 seem to be mediated by interrupting the early-activated intracellular signaling cascades composed of phosphoinositide 3-kinase (PI3K)/Akt and NF-kappaB but not Janus kinase-2 (JAK-2), extracellular signal-regulated kinase (ERK), p38, or C-Jun N-terminal kinase (JNK), according to pharmacological, biochemical and functional analyses.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Lee JY, Rhee MH, Cho JY. Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells. Naunyn Schmiedebergs Arch Pharmacol. 2008 Apr;377(2):111-24. doi: 10.1007/s00210-008-0266-y. PubMed PMID: 18299817.

[2]Cheon SH, Park JS, Jeong SH, Chung BH, Choi BG, Cho WJ, Kang BH, Lee CO. Synthesis and structure-activity relationship studies of 2,3-dihydroimidazo[2,1-a]isoquinoline analogs as antitumor agents. Arch Pharm Res. 1997 Apr;20(2):138-43. PubMed PMID: 18975191.

[3] Houlihan WJ, Munder PG, Handley DA, Nemecek GA. Preclinical pharmacology and possible mechanism of action of the novel antitumor agent 5-(4'-piperidinomethylphenyl)-2,3-dihydroimidazo [2,1-a]isoquinoline. Arzneimittelforschung. 1995 Oct;45(10):1133-7. PubMed PMID: 8595076.

[4] Houlihan WJ, Munder PG, Handley DA, Cheon SH, Parrino VA. Antitumor activity of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines. J Med Chem. 1995 Jan 20;38(2):234-40. PubMed PMID: 7830265.

[5] Brunton VG, Workman P. In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. Br J Cancer. 1993 May;67(5):989-95. PubMed PMID: 8388233; PubMed Central PMCID: PMC1968438.

6: Koenigsmann M, Zafferani M, Danhauser-Riedl S, Reufi B, Houlihan WJ, Thiel E, Berdel WE. Lack of therapeutic effects of platelet activating factor antagonists in WEHI-3B leukemia, human xenotransplanted colorectal and lung cancer and Lewis-lung tumor in vivo. Cancer Lett. 1992 Dec 24;67(2-3):145-56. PubMed PMID: 1483263.7: Valone FH, Ruis NM. Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor. Immunology. 1992 May;76(1):24-9. PubMed PMID: 1628897; PubMed Central PMCID: PMC1421731.8: Danhauser-Riedl S, Felix SB, Houlihan WJ, Zafferani M, Steinhauser G, Oberberg D, Kalvelage H, Busch R, Rastetter J, Berdel WE. Some antagonists of platelet activating factor are cytotoxic for human malignant cell lines. Cancer Res. 1991 Jan 1;51(1):43-8. PubMed PMID: 1988103.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开